Lotilaner

{{Short description|Chemical compound}}

{{Use dmy dates|date=August 2024}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| image = Lotilaner.svg

| width =

| alt =

| caption =

| pronounce =

| tradename = Credelio, Xdemvy, others

| Drugs.com = {{drugs.com|monograph|lotilaner-eent}}

| MedlinePlus =

| DailyMedID = Lotilaner

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = By mouth, eye drops

| class = Antiparasitic

| ATC_prefix = S01

| ATC_suffix = AX25

| ATC_supplemental = {{ATCvet|P53|BE04}}

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Xdemvy- lotilaner ophthalmic solution solution/ drops | website=DailyMed | date=26 July 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccd9e37c-654e-4e84-8c85-6523457df979 | access-date=23 August 2023}}{{cite web | title=Credelio- lotilaner tablet, chewable | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=427f2ebc-ce24-452b-bbb3-43d4ef8b63b0 | access-date=4 August 2021 | archive-date=5 August 2021 | archive-url=https://web.archive.org/web/20210805060048/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=427f2ebc-ce24-452b-bbb3-43d4ef8b63b0 | url-status=live }}{{cite web | title=Credelio- lotilaner tablet, chewable | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=365b701f-e9a8-458f-90ff-33ca1fb947ca | access-date=4 August 2021 | archive-date=5 August 2021 | archive-url=https://web.archive.org/web/20210805054924/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=365b701f-e9a8-458f-90ff-33ca1fb947ca | url-status=live }}

| legal_EU = Rx-only

| legal_EU_comment = {{cite web | title=Credelio EPAR | website=European Medicines Agency (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/veterinary/EPAR/credelio | access-date=4 August 2021 | archive-date=27 January 2022 | archive-url=https://web.archive.org/web/20220127082517/https://www.ema.europa.eu/en/medicines/veterinary/EPAR/credelio | url-status=live }}{{cite web | title=Lotimax Product information | website=Union Register of veterinary medicinal products | date=29 April 2024 | url=https://ec.europa.eu/health/documents/community-register/html/v311.htm | access-date=29 August 2024}}

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 1369852-71-0

| CAS_supplemental =

| PubChem = 76959255

| IUPHAR_ligand =

| DrugBank = DB17992

| ChemSpiderID = 32699771

| UNII = HEH4938D7K

| KEGG = D11212

| ChEBI = 229657

| ChEMBL = 3707310

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = TP-03

| IUPAC_name = 3-Methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]thiophene-2-carboxamide

| C=20 | H=14 | Cl=3 | F=6 | N=3 | O=3 | S=1

| SMILES = Cc1cc(C2=NO[C@@](c3cc(Cl)c(Cl)c(Cl)c3)(C(F)(F)F)C2)sc1C(=O)NCC(=O)NCC(F)(F)F

| StdInChI = 1S/C20H14Cl3F6N3O3S/c1-8-2-13(36-16(8)17(34)30-6-14(33)31-7-19(24,25)26)12-5-18(35-32-12,20(27,28)29)9-3-10(21)15(23)11(22)4-9/h2-4H,5-7H2,1H3,(H,30,34)(H,31,33)/t18-/m0/s1

| StdInChI_comment =

| StdInChIKey = HDKWFBCPLKNOCK-SFHVURJKSA-N

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Lotilaner, sold under the brand name Xdemvy, is an ectoparasiticide (anti-parasitic) medication used for the treatment of blepharitis (inflammation of the eyelid) caused by infestation by Demodex (tiny mites).{{cite web | title=Novel Drug Approvals for 2023 | website=U.S. Food and Drug Administration (FDA) | date=25 July 2023 | url=https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023 | access-date=5 August 2023 | archive-date=21 January 2023 | archive-url=https://web.archive.org/web/20230121035617/https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023 | url-status=dead }} It is used as an eye drop.

It was approved for medical use in the United States in July 2023.{{cite web | title=Xdemvy: FDA-Approved Drugs | publisher=U.S. Food and Drug Administration (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217603 | access-date=5 August 2023 | archive-date=27 July 2023 | archive-url=https://web.archive.org/web/20230727150956/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217603 | url-status=live }}{{cite press release | title=FDA Approves Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis | publisher=Tarsus Pharmaceuticals | via=GlobeNewswire | date=25 July 2023 | url=https://www.globenewswire.com/en/news-release/2023/07/25/2710273/0/en/FDA-Approves-XDEMVY-lotilaner-ophthalmic-solution-0-25-for-the-treatment-of-Demodex-blepharitis.html | access-date=5 August 2023}} The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.{{cite report | title=New Drug Therapy Approvals 2023 | website=U.S. Food and Drug Administration (FDA) | date=January 2024 | url=https://www.fda.gov/media/175253/download | format=PDF | access-date=9 January 2024 | archive-url=https://web.archive.org/web/20240110032419/https://www.fda.gov/media/175253/download | archive-date=10 January 2024 | url-status=dead }}